1-10 of 10
Walter Longo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cytogenetic Abnormalities Following CAR T Cell Therapy for B-Cell Malignancies

Na Hyun Kim, Fatima Khamissi, Kathleen Bone, Nathan Kopp, Walter Longo, Bryon D. Johnson, Tyce Kearl, Peiman Hematti, Mehdi Hamadani, Timothy S. Fenske, Nirav N. Shah
Journal: Blood
Blood (2024) 144 (Supplement 1): 3459.
https://doi.org/10.1182/blood-2024-205752
Published: 2024
Journal Articles

Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Sameem Abedin, Fateeha Furqan, Lyndsey Runaas, Walter Longo, Nirav N. Shah, Timothy S. Fenske, Marcelo C. Pasquini, William R Drobyski, Xue-Zhong Yu, Mehdi Hamadani
Journal: Blood
Blood (2024) 144 (Supplement 1): 1039.
https://doi.org/10.1182/blood-2024-200832
Published: 2024
Journal Articles

Phase 1 Study of Trispecific Anti-CD20, Anti-CD19, Anti-CD22 (CAR20.19.22) T Cells for Relapsed, Refractory B-Cell Malignancies

Nirav N. Shah, Aniko Szabo, Tyce Kearl, Dina Schneider, Walter Longo, Bryon D. Johnson, Peiman Hematti, Mehdi Hamadani, Timothy S. Fenske
Journal: Blood
Blood (2024) 144 (Supplement 1): 3448.
https://doi.org/10.1182/blood-2024-200899
Published: 2024
Journal Articles

Ruxolitinib Resistance or Intolerance in Steroid-Refractory Chronic Graft-Versus-Host Disease - a Real-World Single Center Analysis

Gulrayz Ahmed, Amer Al Homssi, Ramsha Ahmed, Walter Longo, Nirav N. Shah, Lyndsey Runaas, Marcelo C. Pasquini, Timothy S. Fenske, Lisa E Rein, Aniko Szabo, Mehdi Hamadani, Sameem Abedin
Journal: Blood
Blood (2024) 144 (Supplement 1): 7346.
https://doi.org/10.1182/blood-2024-209225
Published: 2024
Journal Articles

Split-Dose R-CHOP for Older Patients with Treatment Naïve DLBCL

Adam Kidwell, Fateeha Furqan, Emilie Aschenbrenner, Walter Longo, Sumana Devata, Mehdi Hamadani, Timothy S. Fenske, Nirav N. Shah
Journal: Blood
Blood (2024) 144 (Supplement 1): 2374.
https://doi.org/10.1182/blood-2024-203974
Published: 2024
Journal Articles

Real-World Experience with RTOG 0227 Induction for First Line Therapy of Primary CNS Lymphoma (PCNSL)

Ramsha Ahmed, Precious Anyanwu, Nirav N. Shah, Mehdi Hamadani, Walter Longo, Sumana Devata, Julie Pruett, Jennifer Connelly, Joseph Bovi, Malika Siker, Christopher Schultz, Timothy S. Fenske
Journal: Blood
Blood (2023) 142 (Supplement 1): 3122.
https://doi.org/10.1182/blood-2023-190961
Published: 2023
Journal Articles

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Tyce Kearl, Anthony Zamora, Jessica Neumann, Parameswaran N. Hari, Dina Schneider, Walter Longo, Peiman Hematti, Bryon D. Johnson, Mehdi Hamadani, Timothy S. Fenske
Journal: Blood
Blood (2023) 142 (Supplement 1): 1024.
https://doi.org/10.1182/blood-2023-173954
Published: 2023
Journal Articles

The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).

Natalie Scott Callander, MD, Stephanie Markovina, BA, Mark B. Juckett, MD, Elizabeth Wagner, MA, Jill Kolesar, Walter Longo, Eliot C. Williams, MD, PhD, Kyungmann Kim, Jae Werndli, BSc, MSc, Shigeki Miyamoto, PhD
Journal: Blood
Blood (2009) 114 (22): 3885.
https://doi.org/10.1182/blood.V114.22.3885.3885
Published: 2009
Journal Articles

VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network

Brad Kahl, Julie Chang, Jens Eickhoff, Leslie Gilbert, Eric Rogers, Jae Werndli, Michael Huie, Thomas McFarland, Michael Volk, Jules H. Blank, Natalie Callander, Walter Longo, Christopher Peterson
Journal: Blood
Blood (2008) 112 (11): 265.
https://doi.org/10.1182/blood.V112.11.265.265
Published: 2008
Journal Articles

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Martha Raschko, MD, Stephanie Markovina, Shigeki Miyamoto, PhD, Walter Longo, MD, Eliot Williams, MD, Thomas McFarland, MD, Jae Werndli, Elisabeth Wagner, Mark Juckett, MD, Natalie Callander, MD
Journal: Blood
Blood (2007) 110 (11): 1173.
https://doi.org/10.1182/blood.V110.11.1173.1173
Published: 2007